Invesco Ltd. Bei Gene, Ltd. Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Invesco Ltd. holds 1,742 shares of BGNE stock, worth $394,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,742

Previous 2,022 13.85%

Holding current value

$394,928

Previous $458,000 13.97%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	N/A	-280 Reduced 13.85%	1,742 $394,000
Q1 2025 May 12, 2025	BUY	$175.1 - $226.71 $2,101 - $2,720	12 Added 0.6%	2,022 $458,000
Q4 2024 Feb 13, 2025	SELL	$174.72 - $246.04 $3.62 Million - $5.09 Million	-20,697 Reduced 91.15%	2,010 $371,000
Q3 2024 Nov 12, 2024	SELL	$143.93 - $224.51 $12.8 Million - $19.9 Million	-88,602 Reduced 79.6%	22,707 $5.1 Million
Q2 2024 Aug 13, 2024	SELL	$129.52 - $174.32 $12.3 Million - $16.5 Million	-94,849 Reduced 46.01%	111,309 $15.9 Million
Q1 2024 May 14, 2024	SELL	$141.8 - $181.47 $38.2 Million - $48.9 Million	-269,727 Reduced 56.68%	206,158 $32.2 Million
Q4 2023 Feb 12, 2024	SELL	$158.67 - $201.58 $160 Million - $204 Million	-1,011,299 Reduced 68.0%	475,885 $85.8 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $12.8 Million - $16 Million	-71,187 Reduced 4.57%	1,487,184 $267 Million
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $2.49 Million - $3.73 Million	-13,970 Reduced 0.89%	1,558,371 $278 Million
Q1 2023 May 12, 2023	SELL	$215.53 - $274.5 $290 Million - $370 Million	-1,347,358 Reduced 46.15%	1,572,341 $339 Million
Q4 2022 Feb 13, 2023	BUY	$125.51 - $229.3 $13.9 Million - $25.3 Million	110,524 Added 3.93%	2,919,699 $642 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $10.6 Million - $16.3 Million	80,471 Added 2.95%	2,809,175 $379 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $538,091 - $959,910	4,443 Added 0.16%	2,728,704 $442 Million
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $40.7 Million - $74.9 Million	-277,956 Reduced 9.26%	2,724,261 $514 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $14.4 Million - $22.6 Million	-58,075 Reduced 1.9%	3,002,217 $813 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $145 Million - $234 Million	580,484 Added 23.41%	3,060,292 $1.11 Billion
Q2 2021 Aug 17, 2021	SELL	$292.75 - $367.01 $2.54 Million - $3.19 Million	-8,692 Reduced 0.35%	2,479,808 $851 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $436 Million - $639 Million	1,671,448 Added 204.57%	2,488,500 $866 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $41.3 Million - $59.1 Million	-186,799 Reduced 18.61%	817,052 $211 Million
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $24.8 Million - $37.5 Million	131,038 Added 15.01%	1,003,851 $288 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $26.2 Million - $41.4 Million	211,743 Added 32.03%	872,813 $164 Million
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $4.33 Million - $6.15 Million	35,523 Added 5.68%	661,070 $81.4 Million
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $48.7 Million - $87.6 Million	420,637 Added 205.28%	625,547 $104 Million
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $38.7 Million - $47.6 Million	-321,164 Reduced 61.05%	204,910 $25.1 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $59.1 Million - $76.1 Million	518,127 Added 6519.78%	526,074 $65.2 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $90,395 - $111,746	-736 Reduced 8.48%	7,947 $1.05 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $929,167 - $1.52 Million	8,683 New	8,683 $1.22 Million

Others Institutions Holding BGNE

# of Institutions

269

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account